Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 1/20 | 0.45 |
| ▸ | BTK | Q06187 | 1/20 | 0.45 |
| ▸ | SUV39H2 | Q9H5I1 | 12/20 | 0.43 |
| ▸ | PIM1 | P11309 | 1/20 | 0.43 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.43 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.43 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 2/20 | 0.40 |
| ▸ | CKS1B | P61024 | 1/20 | 0.40 |
| ▸ | SKP1 | P63208 | 1/20 | 0.40 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13719244 | 0.94 | BTK (0.52) | JAK3BTKSUV39H2 | |
| SCHEMBL13719245 | 0.94 | BTK (0.52) | JAK3BTKSUV39H2 | |
| SCHEMBL13719901 | 0.88 | PIM1 (0.42) | SUV39H2PIM1PIM3PIM2SMPD3 | |
| SCHEMBL12518932 | 0.87 | BTK (0.54) | JAK3BTKSUV39H2 | |
| SCHEMBL12517537 | 0.84 | JAK3 (0.46) | JAK3BTKSUV39H2PIM1PIM3 | |
| SCHEMBL12518941 | 0.84 | BTK (0.51) | JAK3BTKSUV39H2 | |
| SCHEMBL13719662 | 0.84 | BTK (0.53) | JAK3BTKSUV39H2 | |
| SCHEMBL27814300 | 0.84 | BTK (0.51) | JAK3BTKSUV39H2 | |
| SCHEMBL12518926 | 0.83 | BTK (0.45) | JAK3BTKPIM1PIM3PIM2 | |
| SCHEMBL13719291 | 0.82 | BTK (0.49) | JAK3BTKSUV39H2PIM1PIM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2524917-B1 | FUSED PYRIDINE DERIVATIVES | SIHUAN PHARMACEUTICAL HOLDINGS GROUP LTD (CN) | 2018-06-27 | — | — | EP | disclosed |
| US-8680089-B2 | Fused pyridine derivatives | Xuanzhu Pharma Co., Ltd. (CN) | 2014-03-25 | — | — | US | disclosed |
| US-8680089-B2 | Fused pyridine derivatives | Xuanzhu Pharma Co., Ltd. (CN) | 2014-03-25 | — | — | US | disclosed |
| US-8680089-B2 | Fused pyridine derivatives | Xuanzhu Pharma Co., Ltd. (CN) | 2014-03-25 | — | — | US | disclosed |
| EP-2524917-A1 | FUSED PYRIDINE DERIVATIVES | Xuanzhu Pharmaco., Ltd. (CN) | 2012-11-21 | — | — | EP | disclosed |
| US-20120289497-A1 | FUSED PYRIDINE DERIVATIVES | Xuanzhu Pharma Co., Ltd. (CN) | 2012-11-15 | — | — | US | disclosed |
| US-20120289497-A1 | FUSED PYRIDINE DERIVATIVES | Xuanzhu Pharma Co., Ltd. (CN) | 2012-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120289497-A1 | FUSED PYRIDINE DERIVATIVES | GPR119, INSR, IAPP | JAK3 566/4885BTK 1042/4885SUV39H2 3542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.